Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with unmet medical need. Co.'s portfolio of assets include: ARCALYST® (rilonacept) is for the treatment of Cryopyrin-Associated Periodic Syndrome; mavrilimumab is targeting granulocyte-macrophage colony stimulating factor receptor alpha; vixarelimab is evaluating vixarelimab for the potential treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404 is a humanized monoclonal antibody that is designed to inhibit the CD40-CD154 interaction. The KNSA stock yearly return is shown above.
The yearly return on the KNSA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the KNSA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|